Relmada Therapeutics Management

Management criteria checks 2/4

Relmada Therapeutics' CEO is Sergio Traversa, appointed in Apr 2012, has a tenure of 12.08 years. total yearly compensation is $4.78M, comprised of 14.7% salary and 85.3% bonuses, including company stock and options. directly owns 0.81% of the company’s shares, worth €730.63K. The average tenure of the management team and the board of directors is 4.3 years and 4.3 years respectively.

Key information

Sergio Traversa

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage	14.7%
CEO tenure	12.1yrs
CEO ownership	0.8%
Management average tenure	4.3yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sergio Traversa's remuneration changed compared to Relmada Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$94m
Dec 31 2023	US$5m	US$701k	-US$99m
Sep 30 2023	n/a	n/a	-US$112m
Jun 30 2023	n/a	n/a	-US$129m
Mar 31 2023	n/a	n/a	-US$144m
Dec 31 2022	US$3m	US$668k	-US$157m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$157m
Mar 31 2022	n/a	n/a	-US$143m
Dec 31 2021	US$36m	US$630k	-US$126m
Sep 30 2021	n/a	n/a	-US$112m
Jun 30 2021	n/a	n/a	-US$86m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$900k	US$600k	-US$59m
Sep 30 2020	n/a	n/a	-US$43m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$23m
Dec 31 2019	US$16m	US$214k	-US$15m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$17m
Dec 31 2018	n/a	n/a	-US$17m
Sep 30 2018	n/a	n/a	-US$11m
Jun 30 2018	US$975k	US$376k	-US$9m
Mar 31 2018	n/a	n/a	-US$7m
Dec 31 2017	n/a	n/a	-US$6m
Sep 30 2017	n/a	n/a	-US$6m
Jun 30 2017	US$405k	US$350k	-US$6m

Compensation vs Market: Sergio's total compensation ($USD4.78M) is above average for companies of similar size in the German market ($USD385.73K).

Compensation vs Earnings: Sergio's compensation has increased whilst the company is unprofitable.

CEO

Sergio Traversa (63 yo)

12.1yrs

Tenure

US$4,778,944

Compensation

Dr. Sergio Traversa, PharmD, MBA has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relmada Th...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sergio Traversa	CEO & Director	12.1yrs	US$4.78m	0.81% $ 730.6k
Maged Shenouda	Chief Financial Officer	4.3yrs	US$2.34m	0.12% $ 104.5k
Charles Ence	Chief Accounting & Compliance Officer	4.3yrs	US$2.33m	0.13% $ 116.7k
Paolo Manfredi	Chief Scientific Officer	3.6yrs	no data	no data
Gina DiGuglielmo	VP & Head of Clinical Operations	5.1yrs	no data	no data
Marco Pappagallo	Chief Clinical Officer	3.6yrs	no data	no data
John Hixon	Head of Commercial	1.8yrs	no data	no data
Andrew Cutler	Senior Clinical Development Advisor	no data	no data	no data
Richard Mangano	Consultant	7.1yrs	no data	no data

4.3yrs

Average Tenure

62yo

Average Age

Experienced Management: 4E2's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sergio Traversa	CEO & Director	12.1yrs	US$4.78m	0.81% $ 730.6k
Maged Shenouda	Chief Financial Officer	4.3yrs	US$2.34m	0.12% $ 104.5k
Charles Casamento	Independent Chairman of the Board	8.8yrs	US$674.90k	0% $ 0
Stephen Stahl	Member of Scientific Advisory Board	4.3yrs	no data	no data
Maurizio Fava	Member of Scientific Advisory Board	6.9yrs	no data	no data
Fabiana Fedeli	Independent Director	1.3yrs	US$1.33m	0% $ 0
Paul Kelly	Director	8.5yrs	US$1.67m	0.62% $ 560.8k
Charles Inturrisi	Member of Scientific Advisory Board	no data	no data	no data
John Glasspool	Independent Director	4.4yrs	US$604.77k	no data
Luca Pani	Member of Scientific Advisory Board	4.3yrs	no data	no data
Dan Iosifescu	Member of Scientific Advisory Board	4.3yrs	no data	no data
Sanjay Mathew	Member of Scientific Advisory Board	4.3yrs	no data	no data

4.3yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 4E2's board of directors are considered experienced (4.3 years average tenure).

Relmada Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024

CEO & Director recently bought €356k worth of stock

Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors

Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer

CEO & Director recently bought €110k worth of stock

High number of new and inexperienced directors

Recent updates

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024

Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024

CEO & Director recently bought €356k worth of stock

Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023

Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder

New major risk - Revenue and earnings growth

Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value Index

Relmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors

Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer

CEO & Director recently bought €110k worth of stock

Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder

High number of new and inexperienced directors

Relmada Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive Disorder

Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

Relmada Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial

Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology

High number of new and inexperienced directors

Relmada Therapeutics, Inc., Annual General Meeting, May 25, 2022

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse Potential

Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of Psychiatry

Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Relmada Therapeutics, Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day high: €31.40

New 90-day high: €30.80

Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development

Relmada Therapeutics, Inc. Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder

Relmada Therapeutics Announces Appointments of New Executive

New 90-day low: €28.20

New 90-day low - €30.00

New 90-day low - €32.60

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age